Danaher Corporation is poised to acquire Masimo Corporation in a deal valued at approximately $9.9 billion, a move that signals Danaher’s continued expansion within the diagnostics and patient monitoring sectors. The agreement, announced on Tuesday, February 17, 2026, will see Danaher purchase all outstanding shares of Masimo common stock for $180 per share in cash, according to a press release. This Danaher acquisition of Masimo is expected to close in late 2026 or early 2027, pending regulatory approvals and customary closing conditions.
The deal allows Danaher, a global science and technology innovator known for its tools and technologies supporting pharmaceutical development and manufacturing, to broaden its reach into specialized diagnostics. Masimo is a leading provider of pulse oximetry and other patient monitoring solutions, primarily used in acute care settings. The acquisition is anticipated to strengthen Danaher’s Diagnostics segment, which already includes Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics.
Strategic Fit and Synergies
Rainer M. Blair, President and Chief Executive Officer of Danaher, expressed enthusiasm about the acquisition, stating, “We are excited to welcome the Masimo team to Danaher. We’ve followed this innovative company for many years and see it as an exceptional strategic fit for Danaher.” He highlighted Masimo’s leadership in pulse oximetry and its trusted brand as key factors driving the decision. The transaction multiple is approximately 18x estimated 2027 EBITDA, or 15x 2027 estimated EBITDA when factoring in expected annual synergies, as detailed in the Danaher press release.
Julie Sawyer Montgomery, Executive Vice President for Diagnostics at Danaher, emphasized the technological advantages Masimo brings to the table. “Masimo’s advanced sensor technology and AI-enabled monitoring bring powerful novel capabilities to our diagnostics portfolio,” she said. “Integrating these strengths into Danaher will create meaningful opportunities to innovate for clinicians and improve decision making in critical settings.”
Impact on the Diagnostics Landscape
The acquisition is expected to have a significant impact on the competitive landscape of the patient monitoring and diagnostics industry. Masimo’s specialized technologies, particularly in pulse oximetry, complement Danaher’s existing portfolio, creating potential for cross-selling and innovation. The combined entity will be better positioned to serve hospitals, clinics, and other healthcare providers with a more comprehensive range of diagnostic solutions.
According to a report by Reuters, the deal was finalized on February 17, 2026. The Financial Times initially reported that Danaher was closing in on the nearly $10 billion deal.
Masimo’s Role Post-Acquisition
Upon completion of the transaction, Masimo will operate as a standalone operating company within Danaher’s Diagnostics segment. This structure is intended to allow Masimo to maintain its focus on innovation and customer service while benefiting from Danaher’s resources and global scale. The integration is expected to leverage the Danaher Business System (DBS), a methodology focused on continuous improvement and operational excellence.
Financial Details and Timeline
The all-cash transaction is valued at $180 per share, representing a total enterprise value of approximately $9.9 billion, including assumed indebtedness and net of acquired cash. Danaher anticipates realizing synergies through operational efficiencies and revenue growth opportunities. The company expects to provide further details regarding the financial impact of the acquisition during its upcoming earnings calls.
The completion of the deal is subject to customary closing conditions, including regulatory approvals. Danaher and Masimo are working closely with regulatory authorities to ensure a smooth and timely closing process. The companies have not yet announced a specific closing date, but anticipate it will occur in late 2026 or early 2027.
This $9.9 billion deal represents a significant investment in the future of diagnostics and patient monitoring, and is expected to drive innovation and improve healthcare outcomes for patients worldwide. The integration of Masimo’s technologies into Danaher’s portfolio will create a powerful force in the industry, capable of addressing the evolving needs of healthcare providers and patients alike.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical or financial advice. Readers should consult with qualified healthcare professionals or financial advisors for personalized guidance.
The next key milestone will be the receipt of regulatory approvals, which Danaher and Masimo are actively pursuing. Updates on the progress of the acquisition will be available on the companies’ investor relations websites. We encourage readers to share their thoughts on this significant development in the healthcare industry and to continue following time.news for further coverage.
